The estimated Net Worth of Dan Goldstein is at least $3.16 Milión dollars as of 13 June 2022. Dan Goldstein owns over 42 units of Haemonetics stock worth over $322,185 and over the last 8 years Dan sold HAE stock worth over $2,834,349.
Dan has made over 27 trades of the Haemonetics stock since 2016, according to the Form 4 filled with the SEC. Most recently Dan sold 42 units of HAE stock worth $2,629 on 13 June 2022.
The largest trade Dan's ever made was selling 4,691 units of Haemonetics stock on 25 October 2016 worth over $257,677. On average, Dan trades about 1,033 units every 69 days since 2016. As of 13 June 2022 Dan still owns at least 4,447 units of Haemonetics stock.
You can see the complete history of Dan Goldstein stock trades at the bottom of the page.
Over the last 21 years, insiders at Haemonetics have traded over $82,114,016 worth of Haemonetics stock and bought 334,931 units worth $14,646,550 . The most active insiders traders include Paul Black, Robert E Abernathy a Brad Nutter. On average, Haemonetics executives and independent directors trade stock every 13 days with the average trade being worth of $539,753. The most recent stock trade was executed by Stewart W Strong on 26 July 2024, trading 4,312 units of HAE stock currently worth $393,039.
haemonetics is the blood management company. our comprehensive portfolio of integrated devices, information management, and consulting services offers blood management solutions for each facet of the blood management continuum. collectively they help improve patient care, ensure patient safety, and reduce costs for blood and plasma collectors, hospitals, and patients around the world. our mission we believe that through proper blood management, our products and services can help our commercial plasma and blood center customers optimize their collection processes. we seek to help ensure a continual supply of high-quality plasma for biopharmaceuticals and blood components for therapeutic use at optimal costs, along with better blood management processes. working with our hospital customers, we seek to prevent a blood transfusion to the patient who doesn’t need one, or, if a transfusion is necessary, to ensure the transfusion of the right blood product, at the right time, in the right
Haemonetics executives and other stock owners filed with the SEC include: